Skye Bioscience, Inc. SKYE
Skye Bioscience, Inc. (Nasdaq: SKYE) is a cardio-renal-metabolic drug developer. Its lead program, Nimacimab, is in Phase 2 for Obesity.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Nimacimab (anti-CB1) | Obesity (CBeyond Phase 2a monotherapy missed primary endpoint Oct 2025; clinical activities terminated) | antibody | Phase 2 |
Recent results and decisions
- Aug 14, 2026discontinued Skye is discontinuing the CBeyond trial and pausing nimacimab development in connection with the Redx/Fibrx merger, citing a changed obesity landscape rather than biology.
Discontinue the CBeyond trial and pause development rather than funding the next phase of development
Filing - Feb 2, 2026positive CBeyond Phase 2a 52-week extension: nimacimab + semaglutide showed 22.3% weight loss vs 19.7% for semaglutide alone (n=7 each, self-selected extension subset).
The total weight loss after 52 weeks of treatment was 22.3%
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.